Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.45 |
| ▸ | BACH1 | O14867 | 2/20 | 0.44 |
| ▸ | MAFK | O60675 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 4/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912021 | 0.86 | NAAA (0.44) | NAAATRPA1BACH1MAFKNPSR1 | |
| SCHEMBL18911837 | 0.86 | NAAA (0.44) | NAAATRPA1BACH1MAFKNPSR1 | |
| SCHEMBL1269248 | 0.86 | NAAA (0.44) | NAAATRPA1BACH1MAFKNPSR1 | |
| SCHEMBL18937400 | 0.80 | NAAA (0.50) | NAAATRPA1BACH1MAFKMIF | |
| SCHEMBL18912028 | 0.79 | NAAA (0.38) | NAAATRPA1BACH1MAFKNPSR1 | |
| SCHEMBL408946 | 0.77 | NPSR1 (0.40) | NPSR1CYP1A2CYP2D6 | |
| SCHEMBL1267765 | 0.76 | — | — | |
| SCHEMBL97249 | 0.76 | CYP1A2 (0.67) | NPSR1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4790313 | 0.76 | NPSR1 (0.39) | NPSR1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL251768 | 0.74 | CYP1A2 (0.64) | NPSR1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116139293-B | Amphiphilic molecule for targeted regulation of tumor angiogenesis and acid response type polypeptide nano-drug for targeted tumor tissue | 河南省肿瘤医院 | 2025-01-21 | — | — | CN | claimed |
| US-20240409995-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. | 2024-12-12 | — | — | US | claimed |
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | claimed |
| CN-116139293-A | Amphiphilic molecule for targeted regulation of tumor angiogenesis and acid response type polypeptide nano-drug for targeted tumor tissue | 河南省肿瘤医院 | 2023-05-23 | — | — | CN | claimed |
| CN-115386245-A | Preparation method and application of lipophilic carbon nitride nanosheet | 浙江理工大学 | 2022-11-25 | — | — | CN | claimed |
| CN-111320750-B | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| CN-109453364-B | Dual-responsiveness nanoparticle and application thereof in tumor inhibition | 郑州大学第一附属医院 | 2021-10-15 | — | — | CN | claimed |
| EP-3383376-B1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-05-12 | — | — | EP | claimed |
| CN-111320750-A | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2020-06-23 | — | — | CN | claimed |
| EP-3383378-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3383376-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| WO-2017095995-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017095993-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-4724235-A | N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-09 | — | — | US | disclosed |
| US-4597902-A | TREATMENT OF CARDIAC ARRHYTHMIAS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | NAAA 3936/4885TRPA1 2138/4885BACH1 1180/4885 |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | NAAA 67/4885TRPA1 2682/4885BACH1 2082/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | NAAA 279/4885TRPA1 1835/4885BACH1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.